Moonlake Immunotherapeutics
A clinical-stage biopharmaceutical company based in Switzerland that develops immunotherapies. The grounding search tool was unavailable during this attempt, so no verified facts could be retrieved; please retry the request to obtain a properly sourced description.
Sold 3.75M
Sold 150.0K
Sold 150.0K
Sold 160.9K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Biotechnology Value Fund II LP +9 co-filersDirector, 10% owner, Director, See Explanation of Responses · 3 transactions | +412.5% | 6.60M | — | — | 3.75M |
| Santos da Silva JorgeChief Executive Officer, Director · 2 transactions | -4.9% | 2.92M | — | — | 150.0K |
| Reich KristianChief Scientific Officer · 3 transactions | -5% | 2.86M | — | — | 150.0K |
| Bodenstedt MatthiasChief Financial Officer · 7 transactions | -12.6% | 1.12M | — | — | 160.9K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 6 months: -4.21M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.